Titles and Affiliations
Goal: To develop strategies to overcome resistance to drugs commonly used to treat triple-negative breast cancer (TNBC).
Impact: TNBC is an aggressive disease with few treatment options. A common drug used against TNBC is a class of chemotherapy drugs called taxanes. While many TNBC may initially respond to taxane therapy, resistance commonly develops. Dr. Jin is working to develop strategies to prevent resistance and improve outcomes for patients with TNBC.
What’s next: Dr. Jin will conduct laboratory studies to characterize the role of a protein called AGGF1 in the development of chemoresistance. He will also test a promising compound that can sensitize TNBC to taxane therapy and improve treatment response.
Effective treatment is lacking for patients with triple-negative breast cancer (TNBC), an often aggressive form of breast cancer. Taxane-based chemotherapy is still the standard of care, but TNBC tumors often develop resistance to this therapy, allowing the cancer to progress. Dr. Jin’s work is unraveling the mechanisms responsible for chemoresistance and is testing strategies to improve response and outcomes for patients with TNBC.
Research area: Improve outcomes for patients with triple negative breast cancer (TNBC) by identifying strategies to prevent drug resistance.
Impact: Drug resistance is a major hurdle in the management of breast cancer. For patients with TNBC, resistance to chemotherapy can further reduce already limited treatment options. While chemoresistance has been around as long as there has been chemotherapy, the underlying causes are poorly understood. In previous research, Dr. Jin identified a factor called AGGF1 involved in the development of resistance to a group of drugs called taxanes that are commonly used to treat TNBC. TNBC tumors with high levels of AGGF1 showed poor response to taxane-based therapies. In his current work he will build on these findings to identify strategies to prevent chemoresistance and improve outcomes for patients with TNBC.
Current investigation: In his American Association for Cancer Research project, supported by BCRF, Dr. Jin will continue to characterize the role of AGGF1 in taxane resistance. He will explore strategies, including an anti-AGGF1 combination approach, to prevent chemoresistance and test a potential biomarker of response that could identify patients most likely to benefit from the combination therapy.
What he’s learned so far: Dr. Jin has determined that AGGF1 confers taxane resistance in TNBC models. He has identified a compound that can inhibit AGGF1 signaling and sensitize TNBC to taxane treatment.
What’s next: Dr. Jin will continue to explore how AGGF1 causes TNBC resistance to taxanes. He will also further evaluate the effectiveness of his novel compound to sensitize TNBC to taxane in a breast cancer model.
Dr. Lingtao Jin is an assistant professor in the Department of Anatomy and Cell Biology at the University of Florida. Dr. Jin received his PhD at the Institute of Biophysics, Chinese Academy of Sciences, China. He completed his postdoctoral training in Dr. Sumin Kang’s laboratory at Emory University, focused on cancer metabolism and protein kinase signaling.
Dr. Jin has published many research articles in journals such as Cancer Cell and received awards such as the American Cancer Society Institutional Research Grant. His lab focuses on identification of metabolic signaling in therapy resistance.